InVivoSIM anti-human CD79b (Polatuzumab Biosimilar)

About InVivoSIM anti-human CD79b (Polatuzumab Biosimilar)

This non-therapeutic biosimilar antibody uses the same variable regions as the therapeutic antibody Polatuzumab, making it ideal for research use. Polatuzumab is a humanized IgG1 monoclonal antibody that targets CD79b, a critical component of the B cell receptor (BCR) complex. CD79b, also known as Igβ, forms a heterodimer with CD79a (Igα) and is essential for signal transduction following antigen engagement of surface immunoglobulin. The CD79a/CD79b complex initiates downstream signaling cascades that regulate B cell development, activation, proliferation, and survival. CD79b is expressed throughout most stages of B cell maturation but is absent from plasma cells and non-B lineage cells. Importantly, CD79b is retained on the surface of many malignant B cells, including those in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, making it an attractive therapeutic and diagnostic target. Polatuzumab serves as the antibody backbone for the FDA-approved antibody-drug conjugate Polatuzumab vedotin, which delivers a cytotoxic MMAE payload to CD79b+ cells. In contrast, this unconjugated biosimilar form lacks any drug conjugation, allowing researchers to study CD79b-specific antibody binding, internalization, and function without the confounding effects of cytotoxicity. This Polatuzumab biosimilar antibody retains the antigen-binding domains of the therapeutic but is produced for non-clinical research use. It is suitable for a range of applications, including flow cytometry, B cell targeting studies, preclinical modeling, and ADC development.